Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

The WHF Roadmap for Reducing CV Morbidity and Mortality Through Prevention and Control of Rheumatic Heart Disease

As a general guide, the Roadmap is meant to serve as the foundation for the development of tailored plans of action to improve RHD control in specific contexts.

Research

Disparity in Mortality From Rheumatic Heart Disease in Indigenous Australians

Indigenous Australians are much more likely to die from Rheumatic Heart Disease than other Australians.

Research

Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveys

Streptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden. As with any vaccine, it is important to evaluate PCV impact, to help guide decision-making and resource-allocation.

Research

Missing voices: Profile and extent of acquired communication disorders in Aboriginal and non-Aboriginal adult stroke survivors in Western Australia

The needs of Aboriginal stroke patients with acquired communication disorder should inform appropriate service design for speech pathology and rehabilitation

Research

Pediatric sepsis in the developing world.

Sepsis is the leading killer of children worldwide, but this is not reflected in estimates of global mortality.

Research

The microbiology of impetigo in Indigenous children: associations between Streptococcus pyogenes, Staphylococcus aureus, scabies, and nasal carriage

Prevalence and antimicrobial resistance of impetigo pathogens in a randomised, controlled trial of impetigo treatment conducted in remote Indigenous communities

Research

Acute rheumatic fever and rheumatic heart disease: Incidence and progression in the Northern Territory of Australia 1997 to 2010

The reduction in ARF recurrence indicates that the RHD control program has improved secondary prophylaxis; a decline in RHD incidence is expected to follow.